TÜBINGEN, Germany, March 18, 2016 – CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the appointment of three seasoned industry experts to its supervisory board. The new advisors are:
These advisors join existing supervisory board members Friedrich von Bohlen, Ph.D. (Chairman), Prof. Wolfgang Hartwig, Ph.D., and Mathias Hothum, Ph.D.
Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated, “We are pleased to welcome these highly-respected experts to CureVac’s supervisory board as we continue to advance our mRNA-based medicines to address significant therapeutic needs and global market opportunities.”
Friedrich von Bohlen, Ph.D., Chairman of CureVac’s supervisory board, said, “We are very much looking forward to establishing a close working relationship with our new members. Benefitting from their extensive pharmaceutical industry experience, we feel well-positioned to continue our successful course in the development of mRNA-based medicines for numerous disease areas and indications.”